Effects of Physical Activity and Restricted Energy Intake on Chemically Induced Mammary Carcinogenesis

Weiqin Jiang, Zongjian Zhu and Henry J. Thompson

Abstract

In the field of energetics and cancer, little attention has been given to whether energy balance directed interventions designed to regulate body weight by increasing energy expenditure versus reducing energy intake have an equivalent effect on the development of breast cancer. The objective of this experiment was to determine the effects on mammary carcinogenesis of physical activity (PA), achieved via running on an activity wheel, or restricted energy intake (RE). Food intake of PA and RE rats was controlled so that both groups had the same net energy balance determined by growth rate, which was 92% of the sedentary control group (SC). A total of 135 female Sprague-Dawley rats were injected with 1-methyl-1-nitrosourea (50 mg/kg) and 7 days thereafter were randomized to either SC, PA, or RE. Mammary cancer incidence was 97.8%, 88.9%, and 84.4% and cancer multiplicity was 3.66, 3.11, and 2.64 cancers/rat in SC, RE, and PA, respectively (SC versus PA, \( P = 0.02 \) for incidence and \( P = 0.03 \) for multiplicity). Analyses of mammary carcinomas revealed that cell proliferation–associated proteins were reduced and caspase-3 activity and proapoptotic proteins were elevated by PA or RE relative to SC (\( P < 0.05 \)). It was observed that these effects may be mediated, in part, by activation of AMP-activated protein kinase and down-regulation of protein kinase B and the mammalian target of rapamycin.

At any age, positive energy balance can result in weight gain. When positive energy balance is excessive over time, it is associated with overweight and obesity that are predisposing factors for several chronic diseases, including breast cancer (1–4). The occurrence of overweight and obesity is increasing in this country and globally at an epidemic rate (5, 6). Clearly, the prevention of excessive weight gain is an important focus of efforts to combat this problem. One of the recommendations that is widely publicized for weight gain prevention is to limit energy intake and increase energy expenditure by being physically active (5, 6). These are sound recommendations; however, it is not clear if limiting weight gain by one method or the other will have the same effect on a disease process such as breast carcinogenesis that is sensitive to energy availability. There are several reasons that a difference in response might be anticipated. They include the following: (a) physical activity (PA) induces a greater flux of energy through the system that could alter redox-sensitive cell signaling via the induction of oxidative stress, whereas restricted energy intake (RE) reduces oxidative stress (7), and (b) PA, depending on its type, intensity, duration, and frequency, induces a proinflammatory response and chronic inflammation, both of which have been associated with enhancing cancer risk in several organ sites, whereas RE is associated with suppression of inflammation (8, 9). To our knowledge, no comparative studies of the effects of these interventions have been published. In this article, we report an initial set of experiments designed to determine the effects of PA and RE on the carcinogenic response in the mammary gland when they exert the same effects on body weight gain and to investigate the mechanisms by which energetically comparable levels of PA or RE exert their effects.

Materials and Methods

Chemicals

Primary antibodies used in this study were anti–cyclin D1, anti–E2F-1, and anti–p27\(^{kip1}\) from Thermo Fisher Scientific; anti–retinoblastoma (Rb), anti–Bcl-2, anti–human inhibitor of apoptosis protein-like protein (hIAP)/human X-linked inhibitor of apoptosis protein (XIAP), and anti–Bax from BD Biosciences; anti–apoptosis protease-activating factor-1 (Apaf-1) from Millipore; and anti–phosphorylated AMP-activated protein kinase (pAMPK; Thr\(^{172}\)), anti–AMPK, anti–phosphorylated acetyl-CoA-carboxylase (pACC; Ser\(^{79}\)), anti–ACC, anti–phosphorylated Akt (pAkt; Ser\(^{67}\)), anti–Akt, anti–phosphorylated mammalian target of rapamycin (pmTOR; Ser\(^{2448}\)), anti–mTOR, anti–phosphorylated p70S6K (pp70S6K; Thr\(^{389}\)), anti–p70S6K, anti–phosphorylated eukaryote initiation factor 4E-binding protein 1 (p4E-BP1; Thr\(^{37/46}\)), anti–4E-BP1, and anti–rabbit immunoglobulin-horseradish peroxidase–conjugated secondary antibody, as well as Lumiglo reagent with peroxide, all from Cell Signaling Technology. Anti–p21\(^{cip1}\) and anti–mouse immunoglobulin-horseradish peroxidase–conjugated secondary antibody were from Santa

Authors’ Affiliation: Cancer Prevention Laboratory, Colorado State University, Fort Collins, Colorado.

Received 9/4/08; revised 12/2/08; accepted 1/13/09; published OnlineFirst 3/31/09.

Grant support: National Cancer Institute, USPHS grant CA100693 and American Institute for Cancer Research grant 04B068.

Requests for reprints: Henry J. Thompson, Cancer Prevention Laboratory, Colorado State University, 1173 Campus Delivery, Fort Collins, CO 80523. Phone: 970-491-7748; Fax: 970-491-3542; E-mail: henry.thompson@colostate.edu.

©2009 American Association for Cancer Research.
doi:10.1158/1940-6207.CAPR-08-0169

Cancer Prev Res 2009;2(4) April 2009 www.aacrjournals.org

338 www.aacrjournals.org
Mouse anti-β-actin primary antibody was obtained from Sigma Chemical Co.

**Experimental design**

One hundred and thirty-five female Sprague-Dawley rats were obtained from Taconic Farms at 20 d of age. At 21 d of age, rats were injected with 50 mg 1-methyl-1-nitrosourea/kg body weight (i.p.) as previously described (10). Rats were housed individually in solid bottomed polycarbonate cages. Six days following carcinogen injection, all rats were evenly randomized into one of three groups: a physically active group (PA), a group given a restricted amount of food (RE), or a sedentary control group (SC). Each PA rat was paired to a RE rat and the amount of food given the RE rat permitted it to gain body weight at the same rate as its PA pair mate. Rats were fed pellet diet (Test-Diet). The composition of the diet included sucrose, casein, maltodextrin, corn oil, cellulose, minerals, silicon dioxide, vitamins, magnesium stearate, and DL-methionine. The energy distribution was protein (20.5%), fat (12.7%), and carbohydrates (66.8%) and the energy density is 3.48 kcal/g. Animal rooms were maintained at 22 ± 1°C with 50% relative humidity and a 12-h light/12-h dark cycle. Rats were weighed daily and palpated for detection of mammary tumors twice per week starting from 29 d after carcinogen treatment. The work reported was reviewed and approved by the Colorado State University Institutional Animal Care and Use Committee and conducted according to the committee guidelines.

**Physical activity**

In this study, a newly developed wheel running instrument was used to investigate how PA affects the carcinogenic process in the mammary gland. This instrument overcomes several problems that have limited the study of PA and cancer in experimental models (reviewed in refs. 11, 12). PA animals were given free access to an activity wheel and their running behavior was reinforced via the periodic distribution of food of a predetermined amount for a prescribed distance run. This process was automated via the use of a pellet dispenser whose function was integrated with the running wheel under computer control. A proximity sensor was used to verify that the animal was actually running in the wheel.

**Necropsy**

Following an overnight fast, rats were killed over a 3-h time interval via inhalation of gaseous carbon dioxide. The sequence in which rats were euthanized was stratified across groups so as to minimize the likelihood that order effects would masquerade as treatment-associated effects. After the rat lost consciousness, blood was directly obtained from the retro-orbital sinus and gravity fed through heparinized capillary tubes (Fisher Scientific) into EDTA-coated tubes (Becton Dickinson) for plasma. The bleeding procedure took ∼1 min/rat. Plasma was isolated by centrifugation at 1,000 × g for 10 min at room temperature.

**Table 1. Effect of PA on final body weight and the carcinogenic response in the mammary gland**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>n</th>
<th>Incidence (%)</th>
<th>No. cancers/rat</th>
<th>Median mass/rat (g)</th>
<th>Final body weight (g)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC</td>
<td>45</td>
<td>97.8</td>
<td>3.66 ± 0.36</td>
<td>0.41</td>
<td>200.5 ± 1.6</td>
</tr>
<tr>
<td>RE</td>
<td>45</td>
<td>88.9</td>
<td>3.11 ± 0.32</td>
<td>0.30</td>
<td>186.8 ± 1.4</td>
</tr>
<tr>
<td>PA</td>
<td>45</td>
<td>84.4†</td>
<td>2.64 ± 0.28‡</td>
<td>0.16</td>
<td>185.0 ± 1.5</td>
</tr>
</tbody>
</table>

*For cancer multiplicity and final body weight, values are means ± SE. For tumor mass, values are medians. Data were analyzed by ANOVA and difference among groups was evaluated Bonferroni.
†P < 0.01, compared with SC.
‡P < 0.05, compared with SC.
Following blood collection and cervical dislocation, rat was then skinned and the skin to which the mammary gland chains were attached was examined under translucent light for detectable mammary pathologies. All grossly detectable mammary gland lesions were excised for histologic classification. When size was sufficient, a piece of mammary carcinomas was evaluated, respectively, by Western blotting. Western blot images of cell cycle regulatory proteins in mammary carcinomas from SC, RE, and PA rats: cyclin D1, E2F-1, Rb, p21<sup>Cip1</sup>, p27<sup>Kip1</sup>, Bcl-2, hILP/XIAP, Bax, Apaf-1, pAMPK (Thr<sup>172</sup>), AMPK, pACC (Ser<sup>17</sup>), ACC, pAkt (Ser<sup>473</sup>), Akt, pmTOR (Ser<sup>2481</sup>), mTOR, p70S6K (Thr<sup>389</sup>), p70S6K, 4E-BP1 (Thr<sup>37/46</sup>), 4E-BP1, and β-actin were determined using specific primary antibodies followed by treatment with the appropriate peroxidase-conjugated secondary antibodies and visualized by LumiGLO reagent Western blotting detection system. The chemiluminescence signal was captured using a ChemiDoc densitometer (Bio-Rad) that is equipped with a charge-coupled device (CCD) camera having a resolution of 1,300 x 1,030 and run under the control of Quantity One software (Bio-Rad) and analyzed by the software. The actin-normalized scanning density data were reported.

### Table 2. Effect of PA on cell proliferation–related molecules in mammary carcinomas

<table>
<thead>
<tr>
<th>Group</th>
<th>SC</th>
<th>RE</th>
<th>PA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclin D1</td>
<td>33.5 ± 3.0</td>
<td>29.4 ± 1.9</td>
<td>25.0 ± 1.4&lt;sup&gt;*&lt;/sup&gt;</td>
</tr>
<tr>
<td>E2F-1</td>
<td>34.3 ± 3.7</td>
<td>32.1 ± 2.9</td>
<td>30.0 ± 2.9</td>
</tr>
<tr>
<td>ppRb</td>
<td>19.3 ± 4.0</td>
<td>9.5 ± 1.1&lt;sup&gt;*&lt;/sup&gt;</td>
<td>14.7 ± 1.2</td>
</tr>
<tr>
<td>pRb</td>
<td>16.8 ± 3.7</td>
<td>9.9 ± 0.7</td>
<td>15.7 ± 1.1</td>
</tr>
<tr>
<td>Rb</td>
<td>16.8 ± 3.4</td>
<td>9.0 ± 0.9&lt;sup&gt;*&lt;/sup&gt;</td>
<td>14.5 ± 0.9</td>
</tr>
<tr>
<td>ppRb/Rb</td>
<td>1.14 ± 0.07</td>
<td>1.05 ± 0.04</td>
<td>1.01 ± 0.04</td>
</tr>
<tr>
<td>ppRb/pRb</td>
<td>1.18 ± 0.16</td>
<td>0.95 ± 0.07</td>
<td>0.95 ± 0.07</td>
</tr>
<tr>
<td>p21&lt;sup&gt;Cip1&lt;/sup&gt;</td>
<td>13.6 ± 7.0</td>
<td>20.5 ± 0.9&lt;sup&gt;†&lt;/sup&gt;</td>
<td>21.0 ± 0.8&lt;sup&gt;†&lt;/sup&gt;</td>
</tr>
<tr>
<td>p27&lt;sup&gt;Kip1&lt;/sup&gt;</td>
<td>32.5 ± 3.4</td>
<td>34.1 ± 3.3</td>
<td>35.8 ± 2.8</td>
</tr>
</tbody>
</table>

NOTE: The levels of proteins (relative absorbance unit × 10<sup>4</sup>) or the ratio of ppRb to Rb and the ratio of ppRb to pRb are shown; values are mean ± SE, n = 7 per treatment group. The images shown in Fig. 2 are those directly acquired from the ChemiDoc work station that is equipped with a CCD camera having a resolution of 1,300 x 1,030. The normalized intensity data from the ChemiDoc were evaluated; statistical analyses were done on the ranks of the absorbance data via multivariate ANOVA as described in Materials and Methods.

<sup>*</sup><i>P</i> < 0.05, compared with SC.

<sup>†</sup><i>P</i> < 0.01, compared with SC.

### Western blotting

Mammary carcinomas were homogenized in lysis buffer [40 mmol/L Tris-HCl (pH 7.5), 1% Triton X-100, 0.25 mol/L sucrose, 3 mmol/L EGTA, 3 mmol/L EDTA, 50 μmol/L β-mercaptoethanol, 1 mmol/L phenylmethylsulfonyl fluoride, complete protease inhibitor cocktail (Calbiochem)]. The lysates were centrifuged at 7,500 x g for 10 min in a tabletop centrifuge at 4°C and clear supernatant fractions were collected and stored at −80°C. The protein concentration was determined by the Bio-Rad protein assay. The Western blot images of cell cycle regulatory proteins in mammary carcinomas were evaluated, respectively, by Western blotting. Following blood collection and cervical dislocation, rat was then skinned and the skin to which the mammary gland chains were attached was examined under translucent light for detectable mammary pathologies. All grossly detectable mammary gland lesions were excised for histologic classification. When size was sufficient, a piece of mammary carcinomas was evaluated, respectively, by Western blotting. Western blot images of cell cycle regulatory proteins in mammary carcinomas from SC, RE, and PA rats: cyclin D1, E2F-1, Rb, p21<sup>Cip1</sup>, p27<sup>Kip1</sup>, Bcl-2, hILP/XIAP, Bax, Apaf-1, pAMPK (Thr<sup>172</sup>), AMPK, pACC (Ser<sup>17</sup>), ACC, pAkt (Ser<sup>473</sup>), Akt, pmTOR (Ser<sup>2481</sup>), mTOR, p70S6K (Thr<sup>389</sup>), p70S6K, 4E-BP1 (Thr<sup>37/46</sup>), 4E-BP1, and β-actin were determined using specific primary antibodies followed by treatment with the appropriate peroxidase-conjugated secondary antibodies and visualized by LumiGLO reagent Western blotting detection system. The chemiluminescence signal was captured using a ChemiDoc densitometer (Bio-Rad) that is equipped with a charge-coupled device (CCD) camera having a resolution of 1,300 x 1,030 and run under the control of Quantity One software (Bio-Rad) and analyzed by the software. The actin-normalized scanning density data were reported.

### Statistical analyses

Differences among groups in the incidence and multiplicity of mammary carcinomas were evaluated, respectively, by χ² analysis (14) or ANOVA after square root transformation of tumor count as recommended in ref. 15. Differences among groups in the body weight were analyzed by ANOVA (16). For Western blots, representative western bands were shown in the figures. The data shown in the tables were either the actin-normalized scanning data for proteins involved in cell cycle, apoptosis, and energy-sensing pathways or the ratio of the actual scanning units derived from the densitometric analysis of each Western blot for the phospho-proteins involved in energy-sensing pathways. For statistical analyses, the actin-normalized scanning density data obtained from the ChemiDoc scanner using Quantity One were first rank transformed. This approach is particularly suitable for semiquantitative measurements that are collected as continuously distributed data as is the case with Western blots. The ranked data were then subjected to multivariate ANOVA (17). Ratio data were computed from the scanning units derived from the densitometric analysis (i.e., the arbitrary units of absorbance for variables stated and then the ratios were rank transformed and evaluated via multivariate ANOVA). All analyses were done using Systat statistical analysis software, version 12. Data were also subjected to principal component analysis using the Partek software analysis suite (18).

### Fig. 2. Western blot images of cell cycle regulatory proteins in mammary carcinomas from SC, RE, and PA rats: cyclin D1, E2F-1, Rb, p21<sup>Cip1</sup>, and p27<sup>Kip1</sup>.
**Table 3. Effect of PA on apoptosis-related molecules and activity in mammary carcinomas**

<table>
<thead>
<tr>
<th>Group</th>
<th>SC</th>
<th>RE</th>
<th>PA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bcl-2</td>
<td>23.0 ± 1.7</td>
<td>20.0 ± 0.7</td>
<td>17.5 ± 0.7*</td>
</tr>
<tr>
<td>XIAP</td>
<td>20.9 ± 1.3</td>
<td>18.6 ± 0.9†</td>
<td>15.5 ± 0.5*</td>
</tr>
<tr>
<td>Bax</td>
<td>22.1 ± 1.4</td>
<td>26.1 ± 1.1</td>
<td>27.4 ± 1.7†</td>
</tr>
<tr>
<td>Apaf-1</td>
<td>28.3 ± 1.3</td>
<td>30.6 ± 3.4</td>
<td>30.4 ± 0.9</td>
</tr>
<tr>
<td>Caspase-3 activity</td>
<td>144 ± 4</td>
<td>171 ± 5*</td>
<td>166 ± 8*</td>
</tr>
</tbody>
</table>

NOTE: The levels of proteins (relative absorbance unit × 10³) and caspase-3 activity expressed as nmol/L/min/mg protein of rhodamine 110 that is a caspase-3–catalyzed product of Z-DEVD-R110 substrate are shown; values are mean ± SE, n = 7 per treatment group. The images shown in Fig. 3 are those directly acquired from the ChemiDoc work station that is equipped with a CCD camera having a resolution of 1,300 × 1,030. The normalized intensity data from the ChemiDoc were evaluated; statistical analyses were done on the ranks of the absorbance data via multivariate ANOVA as described in Materials and Methods.

†P < 0.01, compared with SC.
‡P < 0.05, compared with SC.

**Results**

**PA and growth**

A total of 135 rats were assigned to the study: 45 SC rats, 45 PA rats, and 45 RE rats. The average distance run per day by the 45 PA rats was 7,673 ± 525 meters per day or ~5 miles per day. As shown in Fig. 1 rats in the PA or RE groups grew at the same rate throughout the study. By the end of the carcinogenesis experiment, the average final body weight of SC rats (200.5 g) was 8% higher than that of PA (185.0 g) or RE rats (186.8) that differed from PA by <1% (Table 1).

**Carcinogenic response**

Greater than 97% of the mammary tumors detected at necropsy were adenocarcinomas and the distribution of benign versus malignant tumors did not differ by treatment group (data not shown). The effect of PA on the carcinogenic response is shown in Table 1 and Fig. 1B and C. Mammary cancer incidence was 97.8%, 88.9%, and 84.4% and cancer multiplicity was 3.66, 3.11, and 2.64 cancers/rat in SC, RE, and PA, respectively (SC versus PA, P = 0.02 for incidence and P = 0.03 for multiplicity). The median tumor mass per rat was reduced by PA or RE compared with SC, which was 0.41, 0.30, and 0.16 in SC, RE, and PA, respectively.

**Cell proliferation and apoptosis**

Mammary carcinomas were analyzed by Western blotting and activity assay for proteins involved in cell proliferation and apoptosis. Table 2 and Fig. 2 provide the average values for each protein assessed and show the Western blots for these proteins for each carcinoma that was evaluated. Levels of cyclin D1, hyperphosphorylated Rb (ppRb), and E2F-1 were reduced and p21 and p27 were elevated in PA versus SC and the response in RE was intermediate to that observed in PA and SC. Multivariate ANOVA indicated that the pattern of change observed was significant (Hotelling-Lawley statistic, P = 0.0026) with the univariate statistics, indicating that the greatest effects were on cyclin D1 (P = 0.046), p21 (P < 0.0006), and ppRb (P = 0.039).

Table 3 and Fig. 3 show caspase-3 activity, an indicator of apoptosis induction and Western blots for proteins involved in apoptosis. Caspase-3 activity was induced by PA or RE relative to SC (P < 0.001). Mammary carcinomas from PA rats had lower levels of Bcl-2 and XIAP and higher levels of Bax, Apaf-1, and caspase-3 activity (similar effect was also observed in mammary gland; data not shown) than found in carcinomas from SC rats. The levels observed in carcinomas from RE rats were intermediate to those observed in PA and SC carcinomas. This pattern of protein expression is consistent with PA inducing a proapoptotic environment (Hotelling-Lawley multivariate statistic, P = 0.018). Univariate statistics from the multivariate analysis indicated that the effects of PA on Bax (P = 0.044), Bcl-2 (P = 0.009), and XIAP (P = 0.003) were significant.

**Signaling pathways**

Exploratory analyses were conducted of the hypothesis that PA and RE would be associated with higher levels of activated AMPK and lower levels of activated Akt relative to levels observed in carcinomas from SC rats. Western blots for each protein in the pathway and its phosphorylated counterpart are shown in Fig. 4, and the actual absorbance data normalized to β-actin are in Table 4. These values were used to compute the ratios of phosphorylated to nonphosphorylated protein, which were then rank transformed and analyzed by multivariate ANOVA. The results of the multivariate analysis supported the working hypothesis (Hotelling-Lawley statistic, P = 0.005). The univariate statistics from that analysis indicated that effects were significant on levels of activated AMPK (ratio of pAMPK/AMPK, P < 0.0002), AMPK activity (ratio of pACC/ACC, P = 0.02), and activated Akt (ratio of pAkt/Akt, P = 0.059).
Based on these results, it was predicted that mTOR activity would be lower in mammary carcinomas from PA or RE relative to those from SC rats and that levels of its phosphorylated downstream targets, p70S6K and 4E-BP1, would be reduced. Figure 5 shows Western blots for pmTOR and two of the substrates of activated mTOR, p70S6K and 4E-BP1, and the actual absorbance data normalized to β-actin are in Table 5. Multivariate ANOVA supported the exploratory hypothesis (Hotelling-Lawley statistic, \(P = 0.0004\)). The univariate statistics from that analysis indicated that effects were significant on levels of activated mTOR (ratio of pmTOR/mTOR, \(P = 0.043\)), p70S6K (ratio of pp70S6K/p70S6K, \(P = 0.003\)), and 4E-BP1 (ratio of p4E-BP1/4E-BP1, \(P < 0.0004\)).

### Principal component analysis

Because it can be argued that effects on the carcinogenic response, rates of cell proliferation and apoptosis, and cell signaling within the induced carcinomas are to some degree interrelated, principal component analysis provides a means by which to obtain a composite view of treatment effects via multivariate analysis of those data simultaneously. As shown in Fig. 6, the effects of RE and PA were distinct from SC. The cluster of points in the PA ellipsoid was more condensed than observed in either SC or RE and minimal overlap was observed in the ellipsoids for PA versus RE, suggestive of both common and unique contributions of each intervention to the observed responses.

### Discussion

The goal of the intervention component of this study was to have rats achieve an average amount of PA that models the national recommendation of 10,000 steps using a free wheel so that activity was at low intensity and self-determined, thus modeling the daily activities of living as defined in ref. 6. PA behavior was maintained by food reward that was set so that body weights would differ by ~10% from physically inactive rats that ate freely, a level of restraint on energy balance that could forestall the occurrence of overweight and obesity (19). RE rats were restricted so that each rat grew at the same rate as the PA rat to which it was paired (Fig. 1). The experimental approach worked well. The average distance traveled was 7,673 meters per day, which is similar to the typical distance traversed when an individual walks 10,000 steps per day. The difference in weight gain between SC and either PA or RE rats was 8%. As shown in Table 1 and Fig. 1, under these modest conditions of reduced positive energy balance, both RE and PA decreased cancer incidence and cancer multiplicity; however, only the effect of PA reached the level of statistical significance relative to SC. Although the carcinogenic response was lower in PA versus RE, those differences were not statistically significant. Keeping in mind that PA was low intensity and that moderate to high intensity PA has been reported to be necessary to inhibit breast carcinogenesis in human populations (5) and in certain animal models (20), these data hint at the existence of effects of PA that extend beyond those achieved by RE alone as suggested by the principal component analysis shown in Fig. 6. However, additional experiments are required to determine if distinct effects of PA exist.

Although it can be argued that the tumors induced in response to PA or RE represent failures to the lifestyle interventions, evidence from chemoprevention studies using the 1-methyl-1-nitrosourea model have shown that rates of cell proliferation and apoptosis in mammary carcinomas are predictive of the clinical efficacy of an agent in both reducing cancer risk and in affecting cancer outcomes (21); that work

---

**Table 4. Effect of PA on the molecules of energy-sensing pathway in mammary carcinomas**

<table>
<thead>
<tr>
<th>Group</th>
<th>SC</th>
<th>RE</th>
<th>PA</th>
</tr>
</thead>
<tbody>
<tr>
<td>pAMPK (Thr172)</td>
<td>14.1 ± 1.7</td>
<td>15.5 ± 1.1</td>
<td>17.9 ± 2.6</td>
</tr>
<tr>
<td>AMPK</td>
<td>19.0 ± 2.6</td>
<td>17.5 ± 1.3</td>
<td>15.0 ± 1.3</td>
</tr>
<tr>
<td>pAMPK/AMPK</td>
<td>0.74 ± 0.03</td>
<td>0.89 ± 0.04</td>
<td>1.19 ± 0.06*</td>
</tr>
<tr>
<td>pACC (Ser79)</td>
<td>20.3 ± 1.2</td>
<td>26.8 ± 2.9</td>
<td>26.6 ± 2.2</td>
</tr>
<tr>
<td>ACC</td>
<td>22.8 ± 1.4</td>
<td>24.9 ± 4.8</td>
<td>20.8 ± 2.3</td>
</tr>
<tr>
<td>pACC/ACC</td>
<td>0.89 ± 0.07</td>
<td>1.08 ± 0.13</td>
<td>1.28 ± 0.09†</td>
</tr>
<tr>
<td>pAkt (Ser473)</td>
<td>13.3 ± 0.9</td>
<td>13.9 ± 1.9</td>
<td>9.7 ± 0.8</td>
</tr>
<tr>
<td>Akt</td>
<td>43.1 ± 3.1</td>
<td>49.7 ± 6.0</td>
<td>39.8 ± 3.0</td>
</tr>
<tr>
<td>pAkt/Akt</td>
<td>0.31 ± 0.02</td>
<td>0.28 ± 0.02</td>
<td>0.24 ± 0.01†</td>
</tr>
</tbody>
</table>

NOTE: The levels of proteins (relative absorbance unit × 10^4) or the ratio of phosphorylated to nonphosphorylated protein are shown; values are mean ± SE, \(n = 7\) per treatment group. The images shown in Fig. 4 are those directly acquired from the ChemiDoc work station that is equipped with a CCD camera having a resolution of 1,300 × 1,030. The normalized intensity data from the ChemiDoc were evaluated; statistical analyses were done on the ranks of the absorbance data via multivariate ANOVA as described in Materials and Methods section.

\*P < 0.01, compared with SC.

†P < 0.05, compared with SC.
It will be important to determine if PA affects carcinogenesis by pathways not influenced by RE or if the magnitude of the effect of PA is simply greater than that of RE. Because we have recently reported that one mechanism by which RE affects carcinogenesis is via suppression of mTOR activity by activation of AMPK and the down-regulation of activated Akt (23), this hypothesis was tested. As shown in Tables 4 to 5 and Tables 4 to 5, both RE and PA had similar effects on AMPK and Akt and seemed to down-regulate mTOR and the phosphorylation of its downstream targets. Hence, even under modest conditions of RE and PA when body weights of all rats were considered in the reference range, it seems that energy-sensing pathways of which AMPK and Akt are components are responding to relatively small differences in the magnitude of energy balance that support body weights and growth curves that differ by 8% and that these effects, at least in the case of PA, are inhibiting the post-initiation phase of mammary carcinogenesis.

In summary, considerable evidence indicates that relatively small positive differences between energy intake and energy expenditure over a period of time predispose to the occurrence of overweight and obesity. The results of this study, in which effects on positive energy balance were at a modest level that are associated with excessive weight gain prevention (i.e., on the order of 10%), indicate that limiting energy availability via PA protected against the occurrence of experimentally induced breast cancer. Although RE also reduced the carcinogenic response, the effect did not reach the level of statistical significance. Both PA and RE seemed to act via the same mechanisms, although these experiments could not exclude the possibility that differing mechanism was also involved. What is not known is whether the same finding will hold true when the intensity of PA or the extent to which positive energy balance is reduced is increased. Answers to these questions are not simply an academic exercise. Rather, because little is known about PA cancer dose-response curves, and hormetic responses to PA have been reported for other disorders, more information is needed to guide recommendations for weight control that also are associated with optimal activity in reducing risk for cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Nicholas Fernandez, Vanessa Fitzgerald, John N. McGinley, Elizabeth Neil, Andre Powell, Jennifer Price, Denise Rush, Jennifer Sells, and Jay Waterman for their excellent technical assistance.

Table 5. Effect of PA on the molecules of mTOR and its downstream targets in mammary carcinomas

<table>
<thead>
<tr>
<th>Group</th>
<th>SC</th>
<th>RE</th>
<th>PA</th>
</tr>
</thead>
<tbody>
<tr>
<td>pmTOR (Ser2448)</td>
<td>23.8 ± 2.5</td>
<td>19.5 ± 3.5</td>
<td>15.8 ± 1.5</td>
</tr>
<tr>
<td>mTOR</td>
<td>41.9 ± 4.0</td>
<td>38.5 ± 7.8</td>
<td>32.8 ± 1.8</td>
</tr>
<tr>
<td>pmTOR/mTOR</td>
<td>0.57 ± 0.02</td>
<td>0.51 ± 0.02</td>
<td>0.48 ± 0.03*</td>
</tr>
<tr>
<td>pp70S6K (Thr421/ Ser424)</td>
<td>24.1 ± 0.8</td>
<td>20.6 ± 2.0</td>
<td>14.3 ± 0.9†</td>
</tr>
<tr>
<td>p70S6K</td>
<td>17.6 ± 1.6</td>
<td>22.1 ± 2.8</td>
<td>15.3 ± 1.1</td>
</tr>
<tr>
<td>pp70S6K/p70S6K</td>
<td>1.37 ± 0.08</td>
<td>0.93 ± 0.06†</td>
<td>0.93 ± 0.06†</td>
</tr>
<tr>
<td>p4E-BP1 (Thr37/46)</td>
<td>15.1 ± 1.5</td>
<td>10.5 ± 0.7*</td>
<td>7.7 ± 1.1†</td>
</tr>
<tr>
<td>p4E-BP1</td>
<td>40.6 ± 4.3</td>
<td>36.4 ± 2.3</td>
<td>26.8 ± 3.8†</td>
</tr>
<tr>
<td>p4E-BP1/p4E-BP1</td>
<td>0.37 ± 0.01</td>
<td>0.29 ± 0.02†</td>
<td>0.29 ± 0.01†</td>
</tr>
</tbody>
</table>

NOTE: The levels of proteins (relative absorbance unit × 10^4) or the ratio of phosphorylated to nonphosphorylated protein are shown; values are mean ± SE, n = 7 per treatment group. The images shown in Fig. 5 are those directly acquired from the ChemiDoc work station that is equipped with a CCD camera having a resolution of 1,300 × 1,030. The normalized intensity data from the ChemiDoc were evaluated; statistical analyses were done on the ranks of the absorbance data via multivariate ANOVA as described in Materials and Methods.

†P < 0.05, compared with SC.

‡P < 0.01, compared with SC.

Also indicated that agents that induce apoptosis tend to be more effective clinically than those agents that primarily decrease cell proliferation. Because both RE and PA reduced median tumor size relative to SC (Table 1), we proceeded to determine whether the predominant effects of PA and RE were on cell proliferation or apoptosis. Consistent with our previous reports, evidence was found that RE inhibited cell proliferation by slowing transit through G1-S (Fig. 2; Table 2; refs. 13, 22); however, the predominant effect of RE was on the induction of apoptosis, measured as caspase-3 activity (Fig. 3; Table 3). Induction of apoptosis seemed to be via the mitochondrial pathway. PA had the same effects on both processes; however, the magnitude was greater, although the differences between RE and PA were generally not statistically significant. If additional experiments show that higher intensity PA has greater effects on carcinogenesis than RE, it will be important to determine if PA affects carcinogenesis by pathways not influenced by RE or if the magnitude of the effect of PA is simply greater than that of RE.

Fig. 5. Western blot images of mTOR and its downstream targets in mammary carcinomas from SC, RE, and PA rats: pmTOR (Ser2448), pp70S6 (Thr421/Ser424), and p4E-BP1 (Thr37/46).
References


Cancer Prevention Research

Effects of Physical Activity and Restricted Energy Intake on Chemically Induced Mammary Carcinogenesis

Weiqin Jiang, Zongjian Zhu and Henry J. Thompson

Cancer Prev Res  Published OnlineFirst March 31, 2009.

Updated version

Access the most recent version of this article at:
doi:10.1158/1940-6207.CAPR-08-0169

Supplementary Material

Access the most recent supplemental material at:
http://cancerpreventionresearch.aacrjournals.org/content/suppl/2009/04/10/1940-6207.CAPR-08-0169.DC1

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, use this link http://cancerpreventionresearch.aacrjournals.org/content/early/2009/03/31/1940-6207.CAPR-08-0169.

Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.